查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1714883

自体免疫疾病诊断市场（按产品类型、测试和最终用户划分）—2025 年至 2030 年全球预测

Autoimmune Disease Diagnostics Market by Product, Type, Test, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

自体免疫疾病诊断市场预计到 2024 年将达到 58 亿美元，2025 年将达到 62.2 亿美元，2030 年将达到 89 亿美元，复合年增长率为 7.38%。

主要市场统计数据
基准年2024年 58亿美元
预计年份：2025年 62.2亿美元
预测年份 2030 89亿美元
复合年增长率（%） 7.38%

近年来，自体免疫疾病诊断领域经历了显着的变革，其特点是技术进步迅速、临床理解加深、市场动态不断变化。随着复杂疾病不断挑战传统的诊断方法，相关人员越来越认识到创新、强大和准确的诊断工具的必要性。这项活动探索了不断发展的诊断方法的前景，强调了重新定义自体免疫疾病检测和管理方式的突破性发展和新兴趋势。

现代诊断环境的特征是各学科领域的融合，从分子生物学和免疫学到生物资讯学和精准医学。这种跨领域的合作正在促进检测方法的发展，不仅可以提高诊断的准确性，还可以更深入地了解疾病的发病机制。这种转变是由创新技术、不断发展的法律规范和不断增加的临床数据的整合所推动的，这些数据使医疗保健提供者能够采取更积极主动的方式来患者照护。因此，市场上的现有企业和新兴企业都在大力投资研发，以便在不断变化的市场需求中更好地竞争。

本执行摘要全面概述了当前的市场状况，强调了塑造这一领域的变革性变化，并分析了关键的细分趋势，为策略决策提供资讯。该报告采用深入分析和通俗易懂的叙述相结合的平衡方法，满足了专业人士和决策者的资讯需求，并为自体免疫疾病诊断的未来发展和创新制定了清晰的蓝图。

一场变革将重新定义自体免疫疾病诊断领域

在过去的十年中，自体免疫疾病诊断领域发生了变革性的变化，从根本上重塑了其营运和技术模式。科学研究的不断进步导致了更准确的生物标记和复杂的诊断演算法的开发，显着提高了自体免疫疾病的早期检测。同时，人工智慧和机器学习的融合为临床医生提供了数据主导的视角，以预测疾病进展并制定个人化治疗计划。

一个显着的变化是从传统的诊断方法转向结合血清学测试和分子方法的综合平台。人们越来越重视照护现场诊断，这有助于在临床即时诊断中快速做出决策，从而加速这种变化。监管机构也在更新其标准以跟上这些技术进步，确保在培育竞争创新文化的同时保持品质和精确度不受影响。这些因素共同推动了模式转移，其中诊断不再仅仅作为确认工具，而且是患者护理整体管理和策略规划的关键组成部分。

技术进步也鼓励市场参与企业投资数位转型，从而实现实验室工作流程的数位化和云端基础的数据管理系统的采用。这种数位化转变促进了科学家之间的合作，并实现了支持临床决策的关键数据的无缝交换。这些技术进步正在推动诊断实验室和医疗保健组织从被动护理模式转向主动护理模式，其中早期发现和及时干预构成了患者管理策略的支柱。最终，持续的颠覆性创新和策略合作为更互联、高效和准确的诊断生态系统奠定了基础。

揭示自体免疫疾病诊断中的关键细分洞察

对自体免疫疾病诊断市场的全面分析揭示了丰富的细分洞察，为了解消费行为、产品创新和技术采用提供了一个视窗。细分的关键维度之一是按产品，透过消耗品、检测试剂套件和仪器等角度对市场进行复杂的审视。这些类别不仅反映了诊断测试的技术能力，而且代表了检测开发基础材料和方法的演变。精密仪器需求的不断增长与耗材需求的激增相辅相成，共同推动创新和市场扩张。

另一个重要的分割参数与诊断的自体免疫疾病的类型有关。这个市场的差异在于针对局部自体免疫疾病而非局部自体免疫疾病的诊断方法。这种划分强调了局部疾病与影响多个器官或全身的疾病相比所面临的独特的病理和诊断挑战。了解这些差异对于寻求根据特定临床需求自订诊断解决方案的相关人员来说至关重要，可扩展性和准确性至关重要。

按检查参数细分同样重要。诊断市场调查包括针对自身抗体和免疫反应、发炎标记和常规检测参数的测试。这些差异化方法针对疾病进展和临床表现的各个阶段，并为医疗保健提供者提供对患者病情的细緻了解。将这些诊断测试整合到综合疾病管理方案中，可以提高我们监测疾病进展、预测治疗结果和优化治疗方法的能力。

最后，按最终用户进行细分可以为不同临床环境中的不同需求提供有价值的见解。市场的最终用户包括门诊医疗中心、诊断实验室、医院诊所、研究机构等。这些多样化的应用强调了自体免疫疾病诊断在医疗生态系统中的广泛实用性和关键重要性。透过绘製此类细分洞察，工业公司可以调整其策略，以满足不同客户群的特定需求，确保诊断技术的创新有效地转化为改善患者照护和业务效率。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 自体免疫疾病盛行率不断上升，早期诊断意识不断增强
      • 政府努力改善疾病控制和不断上涨的医疗成本
      • 全球专业诊断实验室的可用性不断提高
    • 限制因素
      • 症状与其他疾病重迭导致假阳性的风险
    • 机会
      • 整合多种自体免疫疾病标记的综合诊断工具的开发
      • 生物感测器在自体免疫疾病诊断上的应用
    • 任务
      • 疾病变异的复杂性影响诊断的准确性和结果
  • 市场区隔分析
    • 产品：检测试剂套件因其能够快速提供结果而变得越来越重要
    • 最终使用者：扩大门诊护理中心对自体免疫疾病诊断的采用，以实现早期疗育策略
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章自体免疫疾病诊断市场（按产品）

  • 介绍
  • 耗材和检测试剂套件
  • 装置

第七章自体免疫疾病诊断市场（按类型）

  • 介绍
  • 局部自体免疫疾病的诊断剂
  • 系统性自体免疫疾病的诊断剂

第 8 章自体免疫疾病诊断市场（按测试）

  • 介绍
  • 自体抗体和免疫学检测
  • 发炎标记物
  • 定期进行实验室检查

第九章自体免疫疾病诊断市场（按最终用户）

  • 介绍
  • 门诊治疗中心
  • 诊断实验室
  • 医院和诊所
  • 研究所

第 10 章美洲自体免疫疾病诊断市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区自体自体免疫疾病诊断市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲的自体免疫疾病诊断市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Abcam plc
  • AESKU.GROUP GmbH & Co. KG
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs
  • Biogenuix Medsystems Private Limited
  • bioMerieux SA
  • Danaher Corporation
  • DSS Imagetech Pvt. Ltd.
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Grifols, SA
  • Hemagen Diagnostics, Inc.
  • Labcorp Holdings Inc.
  • Medical & Biological Laboratories Co. Ltd
  • Menarini Group
  • Merck KGaA
  • Progentec Diagnostics, Inc.
  • Quest Diagnostics
  • Revvity, Inc.
  • RSR Limited
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity BIoTech PLC
  • Werfen Group
Product Code: MRR-436901065F36

The Autoimmune Disease Diagnostics Market was valued at USD 5.80 billion in 2024 and is projected to grow to USD 6.22 billion in 2025, with a CAGR of 7.38%, reaching USD 8.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.80 billion
Estimated Year [2025] USD 6.22 billion
Forecast Year [2030] USD 8.90 billion
CAGR (%) 7.38%

In recent years, the field of autoimmune disease diagnostics has undergone a remarkable evolution characterized by rapid technological advances, enhanced clinical understanding, and shifting market dynamics. As complex disorders continue to challenge traditional diagnostic approaches, stakeholders have increasingly recognized the need for innovative, robust, and precise diagnostic tools. This introductory section sets the stage by exploring the evolving landscape of diagnostic methodologies, highlighting groundbreaking developments and emerging trends that are redefining how autoimmune disorders are detected and managed.

The modern diagnostics environment is marked by a confluence of disciplines, ranging from molecular biology and immunology to bioinformatics and precision medicine. Such cross-disciplinary collaboration has spurred the development of assays that not only improve diagnostic accuracy but also provide deeper insights into disease pathogenesis. This transformation is driven by the convergence of innovative technologies, evolving regulatory frameworks, and a growing body of clinical data that collectively empower healthcare providers to adopt a more proactive approach to patient care. As a result, both established and emerging players in the market are investing significantly in research and development to fortify their competitive positioning amidst ever-changing market demands.

This executive summary provides a comprehensive overview of the current market scenario, articulates the transformative shifts that are shaping the field, and dissects key segmentation trends that inform strategic decision-making. By adopting a balanced approach that combines detailed analysis with an accessible narrative, this report aligns with the information needs of experts and decision-makers alike, establishing a clear roadmap for future growth and innovation in autoimmune disease diagnostics.

Transformative Shifts Redefining the Autoimmune Disease Diagnostics Arena

Over the past decade, the autoimmune disease diagnostics sector has witnessed transformative shifts that are radically reconfiguring its operational and technological paradigms. Ongoing advancements in scientific research have led to more accurate biomarkers and refined diagnostic algorithms that significantly enhance the early identification of autoimmune disorders. Simultaneously, the integration of artificial intelligence and machine learning is providing a data-driven lens through which clinicians can predict disease progression and tailor personalized treatment plans.

A notable shift in the landscape is the transition from conventional diagnostic methodologies to integrated platforms that combine serological testing with molecular approaches. This change is further accelerated by an increased emphasis on point-of-care diagnostics, which facilitate rapid decision-making in clinical settings. Regulatory bodies are also revising standards to accommodate these innovations, ensuring that quality and accuracy remain uncompromised while fostering a climate of competitive innovation. Combined, these factors are driving a paradigm shift where diagnostics are not merely tools for confirmation but serve as critical components in the overall management and strategic planning of patient treatments.

Technological advancements have also propelled market players to invest in digital transformation, leading to the digitization of laboratory workflows and the adoption of cloud-based data management systems. This digital shift is fostering collaboration among scientists and enabling the seamless exchange of critical data that supports clinical decision-making. The evolution of these technologies is empowering diagnostic laboratories and healthcare institutions to transition from reactive to proactive care models, wherein early detection and timely intervention form the backbone of patient management strategies. Ultimately, the disruptive innovations and strategic collaborations currently underway are setting the stage for a more interconnected, efficient, and accurate diagnostics ecosystem.

Unveiling Key Segmentation Insights in Autoimmune Disease Diagnostics

A comprehensive analysis of the autoimmune disease diagnostics market reveals a rich tapestry of segmentation insights that offer a window into consumer behavior, product innovation, and technological adoption. One of the primary dimensions of segmentation is based on product, where the market is intricately studied through the lens of consumables and assay kits as well as instruments. These categories not only reflect the technical capabilities of diagnostic tests but also indicate an evolution in the materials and methodologies that underpin assay development. The growing demand for high-precision instruments complements the surge in consumables, collectively driving innovation and market expansion.

Another critical segmentation parameter revolves around the type of autoimmune condition being diagnosed. The market is differentiated by the deployment of localized autoimmune disease diagnostics as opposed to diagnostics geared towards systemic autoimmune diseases. This division underscores the distinct pathology and diagnostic challenges associated with localized disorders compared to those affecting multiple organs or systems. Understanding these differences is vital for stakeholders aiming to tailor diagnostic solutions to specific clinical needs while ensuring that scalability and accuracy remain at the forefront.

Equally important is the segmentation based on test parameters. The diagnostic market is studied in terms of tests that target autoantibodies and immunologic responses, inflammatory markers, and routine laboratory tests. These differentiated approaches cater to various stages of disease progression and clinical presentations, offering healthcare providers a nuanced understanding of a patient's condition. The integration of these diagnostic tests into comprehensive disease management protocols has enhanced the ability to monitor disease evolution, predict therapeutic outcomes, and optimize treatment modalities.

Finally, segmentation based on end users offers valuable insights into the varied demand across different clinical settings. The market's end user profile includes ambulatory care centers, diagnostic laboratories, hospitals and clinics, and research institutions. This diversity in application underscores the broad utility and critical importance of autoimmune disease diagnostics across healthcare ecosystems. By mapping these segmentation insights, industry players can fine-tune their strategies to meet the specific needs of diverse customer segments, ensuring that innovations in diagnostic technology translate effectively into patient care improvements and operational efficiencies.

Based on Product, market is studied across Consumables & Assay Kits and Instruments.

Based on Type, market is studied across Localized Autoimmune Disease Diagnostics and Systemic Autoimmune Disease Diagnostics.

Based on Test, market is studied across Autoantibodies & Immunologic Test, Inflammatory Markers, and Routine Laboratory Tests.

Based on End Users, market is studied across Ambulatory Care Centers, Diagnostic Laboratories, Hospitals & Clinics, and Research Institutions.

Key Regional Insights Driving Growth and Innovation

A granular examination of the autoimmune disease diagnostics market on a regional level provides a nuanced understanding of growth patterns and innovation drivers. In the Americas, market dynamics are bolstered by a strong healthcare infrastructure, progressive adoption of advanced diagnostic technologies, and a heightened focus on precision medicine. Research and clinical institutions in this region are actively integrating new diagnostic modalities, which is further propelling the need for advanced tools that ensure early and accurate disease detection.

The Europe, Middle East & Africa region is witnessing a steady expansion fueled by collaborative efforts among academic institutions, government bodies, and industry partners. In these areas, harmonization of regulatory frameworks and an increasing emphasis on patient-centric care have accelerated the adoption of innovative diagnostic solutions. This region is also marked by significant investments in research and development, positioning it as a hotbed for pioneering advancements in autoimmune disease diagnostics.

In the Asia-Pacific region, rapid economic growth coupled with an expanding middle class is driving demand for state-of-the-art healthcare services, including cutting-edge diagnostic technologies. The integration of advanced diagnostics into both urban and emerging healthcare ecosystems is not only enhancing disease management but is also creating new avenues for market expansion. These regional insights collectively underline the importance of tailored diagnostic solutions that meet the unique healthcare needs of diverse populations and clinical environments, ensuring that the benefits of technological innovation are realized on a global scale.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Pioneering Innovation in the Autoimmune Diagnostics Market

Leading the charge in the realm of autoimmune disease diagnostics are key industry players that consistently push the boundaries of innovation and quality. Prominent names, including Abbott Laboratories, Abcam plc, AESKU.GROUP GmbH & Co. KG, Bio-Rad Laboratories, Inc., and BioAgilytix Labs, have established themselves as vanguards in developing advanced diagnostic solutions that address both existing and emerging challenges. These organizations have leveraged their deep expertise in immunology and molecular diagnostics to develop assays with enhanced sensitivity and specificity.

Companies such as Biogenuix Medsystems Private Limited and bioMerieux SA have complemented this innovation with robust portfolios that integrate cutting-edge laboratory technologies. Giants like Danaher Corporation and F. Hoffmann-La Roche Ltd. are instrumental in driving large-scale market transformation through strategic investments in research and development and robust global distribution networks. Alongside these, organizations including DSS Imagetech Pvt. Ltd., Exagen Inc., and Grifols, S.A are recognized for their commitment to delivering high-quality diagnostics that cater to a diverse range of clinical settings.

Other influential players such as Hemagen Diagnostics, Inc., Labcorp Holdings Inc., and Medical & Biological Laboratories Co. Ltd have made significant strides in refining their diagnostic assays while ensuring their solutions consistently deliver high performance in clinical settings. The Menarini Group, Merck KGaA, and Progentec Diagnostics, Inc. further exemplify the focus on innovation and operational excellence through their continuous efforts to expand and diversify their diagnostic toolsets. Companies like Quest Diagnostics, Revvity, Inc., and RSR Limited also play a crucial role by offering specialized diagnostic solutions that enhance early detection and precise disease monitoring. Cutting-edge technologies produced by Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and Werfen Group are setting new benchmarks in the diagnostics market, underscoring the importance of strategic investments, collaborative innovation, and unwavering commitment to quality across the industry.

The report delves into recent significant developments in the Autoimmune Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam plc, AESKU.GROUP GmbH & Co. KG, Bio-Rad Laboratories, Inc., BioAgilytix Labs, Biogenuix Medsystems Private Limited, bioMerieux SA, Danaher Corporation, DSS Imagetech Pvt. Ltd., Exagen Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A, Hemagen Diagnostics, Inc., Labcorp Holdings Inc., Medical & Biological Laboratories Co. Ltd, Menarini Group, Merck KGaA, Progentec Diagnostics, Inc., Quest Diagnostics, Revvity, Inc., RSR Limited, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and Werfen Group. Actionable Recommendations for Industry Leaders

Industry leaders and decision-makers must be adept at navigating the multifaceted challenges presented by the rapidly evolving landscape of autoimmune disease diagnostics. To ensure sustained competitive advantage, a series of strategic actions are recommended. First, companies should elevate their investments in research and development initiatives to capitalize on breakthrough technologies that enhance assay sensitivity, specificity, and overall diagnostic accuracy. By actively collaborating with academic institutions and leveraging cross-disciplinary expertise, organizations can expedite the translation of emerging research into clinical applications.

Another critical recommendation is to embrace digital transformation. The integration of data analytics, artificial intelligence, and machine learning into diagnostic protocols can unlock the potential of large datasets, enabling more precise and predictive diagnostics. These technologies offer opportunities not only to improve the robustness of diagnostic insights but also to streamline laboratory workflows and reduce the time-to-result, thereby significantly enhancing patient outcomes.

Engaging in strategic partnerships and alliances is also essential. By forging collaborations with technology vendors, healthcare providers, and regulatory bodies, companies can collectively address market uncertainties and align on common goals for quality and innovation. This collaborative approach is particularly important in an environment where regulatory compliance and rapid technological adaptation are paramount. Moreover, leaders should consider diversifying their product portfolios to cover both consumables and high-end instruments, ensuring that there is a balanced focus on both immediate market needs and long-term strategic innovation.

Finally, it is imperative that organizations maintain a proactive stance towards emerging market trends and regional dynamics. Tailoring solutions to meet the unique demands of diverse clinical settings-whether in high-integrated healthcare environments of the Americas, the regulatory harmonization efforts in Europe, Middle East & Africa, or the dynamic growth markets in Asia-Pacific-will be key to sustaining growth and fostering long-term resilience in the competitive landscape of autoimmune diagnostics.

Conclusion: Embracing the Future of Autoimmune Diagnostics

The journey through the current landscape of autoimmune disease diagnostics underscores significant trends, transformative shifts, and robust segmentation insights that are sculpting the future of healthcare. With technological innovations pushing the boundaries of traditional diagnostics and the integration of digital tools enhancing precision, the market is set on an upward trajectory. The regional diversifications and notable performances of leading companies underscore the widespread and sustained momentum within the industry.

Ultimately, as research continues to unveil deeper insights into the immunologic underpinnings of autoimmune diseases, the evolution of diagnostic tools will play an increasingly pivotal role in personalized patient care. An optimal blend of advanced diagnostic techniques, strategic collaborations, and proactive leadership will be essential in turning these opportunities into tangible benefits for patients and healthcare providers alike. As the diagnostic landscape transforms, the challenges and opportunities that lie ahead will necessitate a commitment to quality, innovation, and collaborative growth.

This comprehensive analysis reaffirms that the future of autoimmune disease diagnostics is not only promising but is also on a clear trajectory towards more integrated, efficient, and patient-centric approaches. Embracing these developments will be critical for all stakeholders committed to making impactful contributions in the realm of healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of autoimmune diseases coupled with increasing awareness for early diagnosis
      • 5.1.1.2. Rising government initiatives and healthcare expenditure for improved disease management
      • 5.1.1.3. Increasing availability of specialized diagnostic laboratories globally
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of false positives due to overlapping symptoms with other medical conditions
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing comprehensive diagnostic tools integrating multiple autoimmune disease markers
      • 5.1.3.2. Adoption of biosensors for autoimmune disease diagnosis
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of disease heterogeneity affecting diagnostic accuracy and outcomes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising significance of assay kits owing to their ability to provide rapid results
    • 5.2.2. End Users: Expanding adoption of autoimmune disease diagnostics among ambulatory care centers for early intervention strategies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autoimmune Disease Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables & Assay Kits
  • 6.3. Instruments

7. Autoimmune Disease Diagnostics Market, by Type

  • 7.1. Introduction
  • 7.2. Localized Autoimmune Disease Diagnostics
  • 7.3. Systemic Autoimmune Disease Diagnostics

8. Autoimmune Disease Diagnostics Market, by Test

  • 8.1. Introduction
  • 8.2. Autoantibodies & Immunologic Test
  • 8.3. Inflammatory Markers
  • 8.4. Routine Laboratory Tests

9. Autoimmune Disease Diagnostics Market, by End Users

  • 9.1. Introduction
  • 9.2. Ambulatory Care Centers
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Clinics
  • 9.5. Research Institutions

10. Americas Autoimmune Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Autoimmune Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Autoimmune Disease Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Augurex Life Sciences Corp. partnered with ARUP Laboratories to include the 14-3-3η protein test
    • 13.3.2. AliveDx announces LumiQ, an automated immunofluorescence assay solution
    • 13.3.3. Argenx SE announced the approval of VYVGART (efgartigimod alfa) in Japan for adults
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abcam plc
  • 3. AESKU.GROUP GmbH & Co. KG
  • 4. Bio-Rad Laboratories, Inc.
  • 5. BioAgilytix Labs
  • 6. Biogenuix Medsystems Private Limited
  • 7. bioMerieux SA
  • 8. Danaher Corporation
  • 9. DSS Imagetech Pvt. Ltd.
  • 10. Exagen Inc.
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Grifols, S.A
  • 13. Hemagen Diagnostics, Inc.
  • 14. Labcorp Holdings Inc.
  • 15. Medical & Biological Laboratories Co. Ltd
  • 16. Menarini Group
  • 17. Merck KGaA
  • 18. Progentec Diagnostics, Inc.
  • 19. Quest Diagnostics
  • 20. Revvity, Inc.
  • 21. RSR Limited
  • 22. Siemens Healthineers AG
  • 23. Thermo Fisher Scientific Inc.
  • 24. Trinity Biotech PLC
  • 25. Werfen Group

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET MULTI-CURRENCY
  • FIGURE 2. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 4. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY LOCALIZED AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ROUTINE LABORATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 190. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 191. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024